Alerts
Poster Presentations
Rheumatoid arthritis - other biologic treatment
FRI0216 Results of a longitudinal review of pulmonary function and safety data in a phase iib clinical programme testing granulocyte-macrophage colony-stimulating factor (GM–CSF) receptor antagonist mavrilimumab for treatment of rheumatoid arthritis (RA)